A magnetic field generator helmet has proven effective in regressing glioblastomas (GBM), a malignant tumor that is the most common and deadliest type of brain cancer in adults. It may have been just one case, but experts are looking at it with great hope.
This procedure was developed by a team of physicians and scientists in the Department of Neurosurgery at the Neurological Institute of Houston, USA, and the results have now been published in the journal Frontiers in Oncology.
Our results open the door to a new world of non-invasive and non-toxic therapies with many exciting possibilities for the future”, said David S. Baskin, director of the Kenneth R. Peak Brain Tumor and Pituitary Treatment Center.
The helmet uses three magnets, which rotate on themselves, connected to a microprocessor, which works using a rechargeable battery.
To prove the effectiveness of this helmet, a 53-year-old man with a brain tumor used the device for five weeks, first in a clinic and then at home, with the help of his wife.
Read more ➡️ https://t.co/Lz2U3x4PcU pic.twitter.com/kfSDVqgtSf
— Frontiers in Oncology (@FrontOncology)
July 26, 2021
Therapy was initially administered for two hours and gradually increased to a maximum of six hours. During this period, the patient’s tumor mass and volume shrank by nearly a third. However, it was not possible to finish the treatment. The man eventually died of another disease, which was not related to cancer. But the autopsy revealed that 31% of the tumor had regressed.
Tests with this prototype could only be carried out because the US regulator gave authorization for a “compassionate treatment”. The patient was selected for this treatment precisely because he was in the terminal phase. According to the doctors, there was nothing to do but try an innovative treatment.
That was exactly what motivated the approval of the treatment by the Food and Drug Administration of the United States, the regulator responsible for the market authorizations, which granted a “compassionate treatment” authorization for this specific case.
Due to the success of the procedure, researchers will soon test it on other patients.
The therapy appears to be safe and effective in the treatment of GBM. The present study is limited by the fact that the treatment has been carried out in only one patient so far. In the future, let’s go andextend it to more patients for more information on the safety and efficacy of this method”, completes the study.